Literature DB >> 25672488

Fucoidan exerts protective effects against diabetic nephropathy related to spontaneous diabetes through the NF-κB signaling pathway in vivo and in vitro.

Yan Wang1, Minghao Nie1, Yanhong Lu1, Rui Wang1, Jin Li1, Bin Yang1, Mingyang Xia1, Haiyang Zhang1, Xiurong Li1.   

Abstract

Fucoidan, an extract of the seaweed, Fucus vesiculosus, has been widely investigated for its antioxidant effects. However, to date and to the best of our knowledge, pathological studies on the effects of fucoidan against diabetic nephropathy (DN) related to spontaneous diabetes have not been carried out. DN is one of the most serious microvascular complications of diabetes. Therefore, in the present study, the effects of fucoidan against DN related to spontaneous diabetes were investigated in vitro and in vivo. Goto-Kakizaki (GK) rats were allowed free access to standard rat food with or without fucoidan for 13 weeks, and Wistar rats were used as controls. Fucoidan did not show any cytotoxicity on glomerular mesangial cells (GMCs) which were separated from rat kidneys. Fasting blood glucose levels were measured using a blood glucose meter, blood urea nitrogen (BUN) and serum creatinine (Cr) levels were measured using an automatic biochemistry analyzer and urine protein levels were measured using an ELISA kit. Collagen Ⅳ levels in the renal cortex were measured using an ELISA kit, and the expression levels of transforming growth factor-β1 (TGF-β1) and fibronectin (FN) in the renal cortex and GMCs, and nuclear factor-κB (NF-κB) in GMCs were determined by western blot analysis. Fasting blood glucose, BUN, serum Cr, urine protein and collagen Ⅳ levels, and the expression of TGF-β1 and FN, as well as NF-κB p65 nuclear translocation all significantly increased in the GK rats compared with the control Wistar rats. The increase in the fasting blood glucose, BUN, serum Cr, urine protein and collagen Ⅳ levels in the renal cortex was reversed in the GK rats which were orally administered fucoidan. The oral administration of fucoidan also decreased the expression of TGF-β1 and FN in the renal cortex and GMCs, as well as the nuclear translocation of NF-κB p65 in the GMCs. Taken together, the data from our in vitro and in vivo experiments indicate that fucoidan attenuates hyperglycemia and prevents or impedes the development of DN related to spontaneous diabetes by attenuating the activation of the NF-κB signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25672488     DOI: 10.3892/ijmm.2015.2095

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  10 in total

1.  A Randomized Placebo-controlled Trial of an Oral Preparation of High Molecular Weight Fucoidan in Patients with Type 2 Diabetes with Evaluation of Taste Sensitivity.

Authors:  Chieko Sakai; Sunao Abe; Minoru Kouzuki; Hisashi Shimohiro; Yoshie Ota; Hironori Sakinada; Tatsuo Takeuchi; Tsuyoshi Okura; Takeshi Kasagi; Keiichi Hanaki
Journal:  Yonago Acta Med       Date:  2019-03-28       Impact factor: 1.641

Review 2.  Rodent models of diabetic nephropathy: their utility and limitations.

Authors:  Munehiro Kitada; Yoshio Ogura; Daisuke Koya
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-11-14

3.  Effects of scavenger receptors-1 class A stimulation on macrophage morphology and highly modified advanced glycation end product-protein phagocytosis.

Authors:  Shinichi Hamasaki; Takuro Kobori; Yui Yamazaki; Atsuhiro Kitaura; Atsuko Niwa; Takashi Nishinaka; Masahiro Nishibori; Shuji Mori; Shinichi Nakao; Hideo Takahashi
Journal:  Sci Rep       Date:  2018-04-12       Impact factor: 4.379

4.  A comparative study of sulphated polysaccharide effects on advanced glycation end-product uptake and scavenger receptor class A level in macrophages.

Authors:  Takashi Nishinaka; Shuji Mori; Yui Yamazaki; Atsuko Niwa; Hidenori Wake; Tadashi Yoshino; Masahiro Nishibori; Hideo Takahashi
Journal:  Diab Vasc Dis Res       Date:  2020 Jan-Feb       Impact factor: 3.291

Review 5.  Brown Algae Carbohydrates: Structures, Pharmaceutical Properties, and Research Challenges.

Authors:  Yanping Li; Yuting Zheng; Ye Zhang; Yuanyuan Yang; Peiyao Wang; Balázs Imre; Ann C Y Wong; Yves S Y Hsieh; Damao Wang
Journal:  Mar Drugs       Date:  2021-10-31       Impact factor: 5.118

Review 6.  Pharmacological Activities of Sulfated Fucose-Rich Polysaccharides after Oral Administration: Perspectives for the Development of New Carbohydrate-Based Drugs.

Authors:  Roberto J C Fonseca; Paulo A S Mourão
Journal:  Mar Drugs       Date:  2021-07-27       Impact factor: 5.118

7.  Network pharmacology study of Yishen capsules in the treatment of diabetic nephropathy.

Authors:  Jingai Fang; Chendan Wang; Jie Zheng; Yuxiang Liu
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752

8.  Fucoidan prevent murine autoimmune diabetes via suppression TLR4-signaling pathways, regulation DC/Treg induced immune tolerance and improving gut microecology.

Authors:  Meilan Xue; Hui Liang; Xinqiang Ji; Ying Liu; Yinlin Ge; Lin Hou; Ting Sun
Journal:  Nutr Metab (Lond)       Date:  2019-12-16       Impact factor: 4.169

9.  Oligo-Fucoidan Improves Diabetes-Induced Renal Fibrosis via Activation of Sirt-1, GLP-1R, and Nrf2/HO-1: An In Vitro and In Vivo Study.

Authors:  Wen-Chun Yu; Ren-Yeong Huang; Tz-Chong Chou
Journal:  Nutrients       Date:  2020-10-08       Impact factor: 5.717

10.  Wogonin Ameliorates Renal Inflammation and Fibrosis by Inhibiting NF-κB and TGF-β1/Smad3 Signaling Pathways in Diabetic Nephropathy.

Authors:  Zhi-Chao Zheng; Wei Zhu; Lei Lei; Xue-Qi Liu; Yong-Gui Wu
Journal:  Drug Des Devel Ther       Date:  2020-10-08       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.